Conrad Mielcuszny

Conrad Mielcuszny serves as CEO at Genesis Biosciences. Genesis Biosciences operates in the research sector with approximately 49.0 employees. The company is headquartered in Lawrenceville, Georgia. Genesis Biosciences generates annual revenue of 35000000.0.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • 2,842 executive contacts are available in Georgia.
• • Our database includes 201,469 c suite-level executives.

Google Cloud Hosting Mobile Friendly Nginx WordPress.org Google Tag Manager Bootstrap Framework

biochemistry microbial products antimicrobial products environmentallyresponsible products biosciences fermentation professional cleaning facilities management cleaning cleaning solutions hygiene solutions biotechnology research eco-benign technology bacillus strains biological remediation wastewater treatment innovative formulations probiotics environmentally responsible performance-driven industrial cleaning marine applications aquaculture solutions horeca sector home care products sanitary solutions waste management biocidal agents quality control scientific validation genomic characterization research & development fermentation facilities technical support natural alternatives chemical-free cleaning plant-derived actives environmental protection sustainable solutions biotechnology disruptive technologies industrial applications sanitation products strain optimization quality assurance fda compliance biological safety environmental science green chemistry efficacy testing environmental challenges market leader technical expertise continuous improvement laboratory testing industry standards

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like Conrad Mielcuszny in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Genesis Biosciences.

Conrad Mielcuszny's Position in the MessageCEO Database

• •2,871 verified executive contacts in research are in the MessageCEO database.
• •2,643 verified executive contacts in Georgia are in the database.
• •23 verified contacts work at research companies in the 49.0 employee range (same size as Genesis Biosciences).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated May 2026.

How do I reach Conrad Mielcuszny directly?

Conrad Mielcuszny's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at Genesis Biosciences. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Conrad Mielcuszny work for?

Conrad Mielcuszny is CEO at Genesis Biosciences, a company in the research sector with 49.0 employees. The company is based in Lawrenceville, Georgia.

Can I pitch or sell to Conrad Mielcuszny?

As CEO at Genesis Biosciences, Conrad Mielcuszny is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Conrad Mielcuszny directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Conrad Mielcuszny in?

Conrad Mielcuszny works in the research industry as CEO at Genesis Biosciences. MessageCEO provides verified contact information for executives across all major industries.

Is Conrad Mielcuszny's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Conrad Mielcuszny's profile is kept up-to-date with the latest available information.

Last updated: May 25, 2026